About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Lawrence M. Prescott, PhD
Marvin M. Goldenberg, PhD, describes new treatments for colorectal, breast, and advanced prostate cancer.
Marvin M. Goldenberg, PhD
Step-Down Treatment of Uncomplicated Gastroesophageal Reflux Disease in Patients Taking Twice-Daily Lansoprazole
It is possible to safely reduce the dose of medication for patients with GERD.
Cameron C. Lindsey, PharmD, Maqual R. Graham, PharmD, and Lauri A. Witt, PharmD
A Prospective Study of Antibiotic Cost Containment in a University Teaching Hospital over a 13-Year Period
A unique antibiotic monitoring program has succeeded in reducing costs.
Arpi G. Kuyumjian, PharmD, Jerome F. Levine, MD, Peter A. Gross, MD, and Antonia Lo Presti, MD
The Impact of NSAID Selection on Gastrointestinal Injury and Risk for Cardiovascular Events: Identifying and Treating Patients at Risk
New COX-1/COX-2 NSAIDs relieve pain with less gastrointestinal damage than past pain relievers but may increase the risk of cardiovascular injury.
Richard L. Ruffalo, MD, PharmD, Robert L. Jackson, MD, and Joshua J. Ofman, MD, MSHS
The authors review the potential gastrointestinal and cardiovascular risks posed by COX-1/COX-2 NSAIDs.
A. Mark Fendrick, MD, and Susan M. Garabedian-Ruffalo, PharmD
The difficulty in educating professionals who prescribe medications is not unlike the challenge of fixing a dangerous road.
Peter Teichman, MD, MPA
Editor-in-Chief David Nash discusses the National Drug and Therapeutic Index.
David B. Nash, MD, MBA
Precautions must be taken when sample medications are dispensed.
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Mr. Barlas discusses the ambiguity of the new federal guidelines for PBMs.
Omalizumab is being touted as a new treatment for patients with allergic disorders.
Boris Nogid, PharmD, and Timothy S. McCall, RPh